Literature DB >> 28342150

Expression and Characterization of Human β-1, 4-Galactosyltransferase 1 (β4GalT1) Using Silkworm-Baculovirus Expression System.

Daisuke Morokuma1, Jian Xu1, Masato Hino1, Hiroaki Mon1, Jasmeen S Merzaban2, Masateru Takahashi3, Takahiro Kusakabe1, Jae Man Lee4.   

Abstract

Baculovirus expression vector system (BEVS) is widely known as a mass-production tool to produce functional recombinant glycoproteins except that it may not be always suitable for medical practice due to the differences in the structure of N-linked glycans between insects and mammalian. Currently, various approaches have been reported to alter N-linked glycan structures of glycoproteins derived from insects into terminally sialylated complex-type N-glycans. In the light of those studies, we also proposed in vitro maturation of N-glycan with mass-produced and purified glycosyltransferases by silkworm-BEVS. β-1,4-Galactosyltransferase 1 (β4GalT1) is known as one of type II transmembrane enzymes that transfer galactose in a β-1, 4 linkage to accepter sugars, and a key enzyme for further sialylation of N-glycans. In this study, we developed a large-scale production of recombinant human β4GalT1 (rhβ4GalT1) with N- or C-terminal tags in silkworm-BEVS. We demonstrated that rhβ4GalT1 is N-glycosylated and without mucin-type glycosylation. Interestingly, we found that purified rhβ4GalT1 from silkworm serum presented higher galactosyltransferase activity than that expressed from cultured mammalian cells. We also validated the UDP-galactose transferase activity of produced rhβ4GalT1 proteins by using protein subtracts from silkworm silk gland. Taken together, rhβ4GalT1 from silkworms can become a valuable tool for producing high-quality recombinant glycoproteins with mammalian-like N-glycans.

Entities:  

Keywords:  Baculovirus expression vector system; N-glycosylation; Silkworm; β-1, 4-Galactosyltransferase 1

Mesh:

Substances:

Year:  2017        PMID: 28342150     DOI: 10.1007/s12033-017-0003-1

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  24 in total

Review 1.  Developing baculovirus-insect cell expression systems for humanized recombinant glycoprotein production.

Authors:  Donald L Jarvis
Journal:  Virology       Date:  2003-05-25       Impact factor: 3.616

2.  Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγ(null) mice.

Authors:  Simon N Robinson; Paul J Simmons; Michael W Thomas; Nathalie Brouard; Jeannie A Javni; Suprita Trilok; Jae-Seung Shim; Hong Yang; David Steiner; William K Decker; Dongxia Xing; Leonard D Shultz; Barbara Savoldo; Gianpietro Dotti; Catherine M Bollard; Leonard Miller; Richard E Champlin; Elizabeth J Shpall; Patrick A Zweidler-McKay
Journal:  Exp Hematol       Date:  2012-02-02       Impact factor: 3.084

Review 3.  Milestones leading to the genetic engineering of baculoviruses as expression vector systems and viral pesticides.

Authors:  Max D Summers
Journal:  Adv Virus Res       Date:  2006       Impact factor: 9.937

4.  Evidence for a molecular distinction between Golgi and cell surface forms of beta 1,4-galactosyltransferase.

Authors:  L C Lopez; A Youakim; S C Evans; B D Shur
Journal:  J Biol Chem       Date:  1991-08-25       Impact factor: 5.157

5.  Mammalian glycosyltransferase expression allows sialoglycoprotein production by baculovirus-infected insect cells.

Authors:  N S Seo; J R Hollister; D L Jarvis
Journal:  Protein Expr Purif       Date:  2001-07       Impact factor: 1.650

6.  Engineering β1,4-galactosyltransferase I to reduce secretion and enhance N-glycan elongation in insect cells.

Authors:  Christoph Geisler; Hideaki Mabashi-Asazuma; Chu-Wei Kuo; Kay-Hooi Khoo; Donald L Jarvis
Journal:  J Biotechnol       Date:  2014-11-25       Impact factor: 3.307

Review 7.  Fulfilling Koch's postulates in glycoscience: HCELL, GPS and translational glycobiology.

Authors:  Robert Sackstein
Journal:  Glycobiology       Date:  2016-02-29       Impact factor: 4.313

8.  Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone.

Authors:  Robert Sackstein; Jasmeen S Merzaban; Derek W Cain; Nilesh M Dagia; Joel A Spencer; Charles P Lin; Roland Wohlgemuth
Journal:  Nat Med       Date:  2008-01-13       Impact factor: 53.440

9.  Functional selectin ligands mediating human CD34(+) cell interactions with bone marrow endothelium are enhanced postnatally.

Authors:  Andrés Hidalgo; Linnea A Weiss; Paul S Frenette
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

10.  Production of a recombinant mouse monoclonal antibody in transgenic silkworm cocoons.

Authors:  Masashi Iizuka; Shingo Ogawa; Atsushi Takeuchi; Shinichi Nakakita; Yuhki Kubo; Yoshitaka Miyawaki; Jun Hirabayashi; Masahiro Tomita
Journal:  FEBS J       Date:  2009-09-09       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.